A Phase 3 interventional study of Dalfampridine 10 MG [Ampyra] and Physical therapy in Multiple Sclerosis, sponsored by MGH Institute of Health Professions. Recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by MGH Institute of Health Professions · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing 4-Aminopyridine in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. 4-Aminopyridine · Multiple Sclerosis.
Among the 27 studies testing 4-Aminopyridine in Multiple Sclerosis, this one is the 17th largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 3, and was the 27th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 27 studies testing 4-Aminopyridine in Multiple Sclerosis is open now, in 1 country.
By country, each count listing its studies:
4-Aminopyridine: first FDA approval 2010 (AMPYRA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 25 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 11 · Phase 4 8
First in 2003; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 48 is close to the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 64 across the 27 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 27 have an industry lead sponsor. The 10 most frequent:
MGH Institute of Health Professions is the lead sponsor of 19 studies on the registry; 12 are open to participants now.
MGH Institute of Health Professions has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing 4-Aminopyridine in Multiple Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing 4-Aminopyridine in Multiple Sclerosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are:
Participants with MS-related mobility deficits will:
Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.
Multiple sclerosis (MS) is a degenerative disease process that disrupts the transmission of nerve impulses, resulting in a range of neurological signs and symptoms. Walking-related impairment is one of the most common symptoms, reported to affect more than 90% of people with MS. The leading non-pharmacological intervention for walking-related deficits in people with MS is rehabilitation, such as physical therapy. Rehabilitation is believed to restore function through experience-dependent neuroplasticity. There is strong evidence that physical therapy can improve mobility-related function in people with MS, and emerging evidence that motor-relearning approaches to rehabilitation may be associated with changes in brain structure and function that correlate with improvements in functional performance. The leading pharmacological intervention for walking-related deficits in people with MS is dalfampridine. Dalfampridine improves motor function by increasing nerve conduction through demyelinated axons, however, dalfampridine alone is not likely to generate neuroplastic changes needed for lasting benefits, because neural plasticity requires salient and task-specific practice with high repetition at adequate intensity, as well as complex environments that stimulate opportunities for movement to facilitate synthesis of neurotrophic factors. Indeed, the treatment effects of dalfampridine are reversed as soon as the treatment was discontinued. However, it is possible that improved nerve conduction velocity provided by dalfampridine may accelerate neuroplasticity generated from rehabilitation. Yet, combining dalfampridine with concurrent rehabilitation has never been studied. The objective of the proposed study is to test our central hypothesis that providing a motor-relearning physical therapy intervention in combination with dalfampridine will produce superior gains to either intervention alone in mobility through augmented neuroplasticity.
Aim 1 will determine if dalfampridine can augment the effects of physical therapy in restoring function in people with MS by comparing the combined intervention to physical therapy without dalfampridine. Aim 2 will explore the comparative effectiveness between the combined intervention with dalfampridine alone, and between physical therapy alone and dalfampridine alone. In Aim 3, the investigators will investigate mechanisms of treatment effects by evaluating functional connectivity before and after each intervention arm. Exploratory Aim 4 will examine whether there are specific clinical and personal factors associated with treatment responsiveness to each type of treatment. The primary efficacy outcome will be percent change from baseline in Timed 25-Foot Walk to enable direct comparison to previous dalfampridine studies. A range of secondary and tertiary clinical outcomes, both objective and self-reported, will examine restoration of function (objective and perceived) beyond just walking speed.
The investigators will enroll 48 participants with MS-related mobility deficits and EDSS ≤6.5. In the first treatment phase, all participants will receive 6 weeks of dalfampridine treatment to assess the effects of this treatment and determine individual responder status for stratified randomization in phase 2. Following 2-week dalfampridine washout and new off-drug baseline assessment, stratified randomization will allocate participants to either 6 weeks of physical therapy with resumed dalfampridine or 6 weeks of physical therapy without dalfampridine. Outcomes will be reassessed after the physical therapy treatment phase. This project tests a novel combination of two traditional interventions to improve mobility in people with MS, with specific aims that investigate both restoration of function and mechanisms of treatment effects using brain imaging outcomes. These two leading, yet distinct approaches for improving mobility in people with MS, may have complementary mechanisms of action leading to enhanced outcomes when combined. The findings generated by this research will inform the design of further studies exploring longer-term outcomes and disease progression trajectories associated with the interventions found to be most effective and tolerable for individuals with MS in this stage of the research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg tablet twice per day
Drug: Dalfampridine 10 MG [Ampyra]
One-on-one outpatient physical therapy twice per week
Behavioral: Physical therapy
10 mg tablet twice per day while receiving one-on-one outpatient physical therapy twice per week
Other: Dalfampridine plus physical therapy
Dalfampridine (10 mg) every 12 hours for 6 weeks.
Also known as: Ampyra
Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
Also known as: Combined drug and behavioral
Change in Timed 25-Foot Walk (T25FW)
The T25FW is a test that times how long in seconds a person can walk 25 feet from standing start as quickly as possible. We will assess the change in T25FW between baseline and end of treatment for each phase of the treatment (1: dalfampridine only run-in; 1: physical therapy with our without dalfampridine)
Time frame: Week 0 to week 6, week 8 to week 14
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.
Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 32 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jun 2024 → Sep 2024, primary completion Dec 2026 → May 2027 and completion Dec 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4-Aminopyridine
MGH Institute of Health Professions